XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.21.2

Equity | 9 Months Ended
--- | ---
Sep. 30, 2021
Equity [Abstract] |
Equity | Equity
| Three Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at July 1, 2020 | 3,577 |  | $ | 1,788 |  | $ | 39,373 |  | $ | 49,724 |  | $ | (6,393) |  | 1,048 |  | $ | (56,850) |  | $ | 102 |  | $ | 27,744 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 2,941 |  | — |  | — |  | — |  | — |  | 2,941 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 10 |  | — |  | — |  | — |  | 10 |
Cash dividends declared on common stock ($0.61 per share) | — |  | — |  | — |  | (1,558) |  | — |  | — |  | — |  | — |  | (1,558) |
Share-based compensation plans and other | — |  | — |  | 116 |  | — |  | — |  | (1) |  | 35 |  | — |  | 151 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 4 |  | 4 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (22) |  | (22) |
Balance at September 30, 2020 | 3,577 |  | $ | 1,788 |  | $ | 39,489 |  | $ | 51,107 |  | $ | (6,383) |  | 1,047 |  | $ | (56,815) |  | $ | 84 |  | $ | 29,270 |
Balance at July 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 4,567 |  | — |  | — |  | — |  | — |  | 4,567 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 38 |  | — |  | — |  | — |  | 38 |
Cash dividends declared on common stock ($0.65 per share) | — |  | — |  | — |  | (1,653) |  | — |  | — |  | — |  | — |  | (1,653) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 8 |  | (583) |  | — |  | (583) |
Share-based compensation plans and other | — |  | — |  | 110 |  | — |  | — |  | — |  | 21 |  | — |  | 131 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 4 |  | 4 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (29) |  | (29) |
Balance at September 30, 2021 | 3,577 |  | 1,788 |  | 44,149 |  | 51,691 |  | (4,590) |  | 1,052 |  | (57,244) |  | 69 |  | 35,863 |
| Nine Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at January 1, 2020 | 3,577 |  | $ | 1,788 |  | $ | 39,660 |  | $ | 46,602 |  | $ | (6,193) |  | 1,038 |  | $ | (55,950) |  | $ | 94 |  | $ | 26,001 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 9,161 |  | — |  | — |  | — |  | — |  | 9,161 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (190) |  | — |  | — |  | — |  | (190) |
Cash dividends declared on common stock ($1.83 per share) | — |  | — |  | — |  | (4,656) |  | — |  | — |  | — |  | — |  | (4,656) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 16 |  | (1,281) |  | — |  | (1,281) |
Share-based compensation plans and other | — |  | — |  | (171) |  | — |  | — |  | (7) |  | 416 |  | — |  | 245 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 12 |  | 12 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (22) |  | (22) |
Balance at September 30, 2020 | 3,577 |  | 1,788 |  | 39,489 |  | 51,107 |  | (6,383) |  | 1,047 |  | (56,815) |  | 84 |  | 29,270 |
Balance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 9,291 |  | — |  | — |  | — |  | — |  | 9,291 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 1,595 |  | — |  | — |  | — |  | 1,595 |
Cash dividends declared on common stock ($1.95 per share) | — |  | — |  | — |  | (4,962) |  | — |  | — |  | — |  | — |  | (4,962) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 11 |  | (822) |  | — |  | (822) |
Spin-off of Organon & Co. | — |  | — |  | 4,643 |  | — |  | 449 |  | — |  | — |  | (1) |  | 5,091 |
Share-based compensation plans and other | — |  | — |  | (82) |  | — |  | — |  | (6) |  | 365 |  | — |  | 283 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 12 |  | 12 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (29) |  | (29) |
Balance at September 30, 2021 | 3,577 |  | 1,788 |  | 44,149 |  | 51,691 |  | (4,590) |  | 1,052 |  | (57,244) |  | 69 |  | 35,863 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration